Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life

Journal of Patient-Reported Outcomes - Tập 4 Số 1 - 2020
Erica Zaiser1, Amy J. Sehnert2, Ashley Duenas1, Sara Saberi3, Ella Brookes1, Matthew Reaney4
1Evidera, London, UK
2MyoKardia, Inc, Brisbane, California, USA
3Frankel Cardiovascular Center, University of Michigan Hospital, Michigan Medicine, Ann Arbor, Michigan, USA
4IQVIA, 3 Forbury Place, 23 Forbury Road, Reading, RG1 3JH, UK

Tóm tắt

Abstract Background Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients’ perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients’ experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them. Methods Development of the HCM conceptual model involved a web-based survey to capture patients’ insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients’ experiences were identified and used to develop a conceptual model of the patient experience with HCM. Results The HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients’ lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM. Conclusions A conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients’ lives. This HCM conceptual model reflecting patients’ experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.

Từ khóa


Tài liệu tham khảo

Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., et al. (2011). 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 124(24), 2761–2796.

Maron, M. S., Olivotto, I., Betocchi, S., Casey, S. A., Lesser, J. R., Losi, M. A., et al. (2003). Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. New England Journal of Medicine, 348(4), 295–303.

Semsarian, C. (2011). Guidelines for the diagnosis and management of hypertrophic cardiomyopathy. Heart, Lung and Circulation, 20(11), 688–690.

Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., et al. (2014). 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35(39), 2733–2779.

Ku, L., Feiger, J., Taylor, M., & Mestroni, L. (2003). Cardiology patient page. Familial dilated cardiomyopathy. Circulation, 108(17), e118–e121.

Maron, B. J., Rowin, E. J., Casey, S. A., Lesser, J. R., Garberich, R. F., McGriff, D. M., et al. (2016). Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation, 133(1), 62–73.

Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., et al. (2018). Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation, 138(14), 1387–1398.

Christiaans, I., van Langen, I. M., Birnie, E., Bonsel, G. J., Wilde, A. A., & Smets, E. M. (2009). Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A cross-sectional cohort study. American Journal of Medical Genetics Part A, 149a(4), 602–612.

Cox, S., O'Donoghue, A. C., McKenna, W. J., & Steptoe, A. (1997). Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart, 78(2), 182–187.

Hershberger, R. E., Morales, A., & Siegfried, J. D. (2010). Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genetics in Medicine, 12(11), 655–667.

Lu, D. Y., Pozios, I., Haileselassie, B., Ventoulis, I., Liu, H., Sorensen, L. L., et al. (2018). Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. Journal of the American Heart Association, 7(5), e006657.

Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009). Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the United States, 1980–2006. Circulation, 119(8), 1085–1092.

Bagnall, R. D., Weintraub, R. G., Ingles, J., Duflou, J., Yeates, L., Lam, L., et al. (2016). A prospective study of sudden cardiac death among children and young adults. New England Journal of Medicine, 374(25), 2441–2452.

Harmon, K. G., Asif, I. M., Maleszewski, J. J., Owens, D. S., Prutkin, J. M., Salerno, J. C., et al. (2015). Incidence, cause, and comparative frequency of sudden cardiac death in National Collegiate Athletic Association Athletes: A decade in review. Circulation, 132(1), 10–19.

Ullal, A. J., Abdelfattah, R. S., Ashley, E. A., & Froelicher, V. F. (2016). Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: A meta-analysis. The American Journal of Medicine, 129(5), 486–496.e2.

Luiten, R. C., Ormond, K., Post, L., Asif, I. M., Wheeler, M. T., & Caleshu, C. (2016). Exercise restrictions trigger psychological difficulty in active and athletic adults with hypertrophic cardiomyopathy. Open Heart, 3(2), e000488.

Reineck, E., Rolston, B., Bragg-Gresham, J. L., Salberg, L., Baty, L., Kumar, S., et al. (2013). Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. The American Journal of Cardiology, 111(7), 1034–1039.

Sweeting, J., Ingles, J., Timperio, A., Patterson, J., Ball, K., & Semsarian, C. (2016). Physical activity in hypertrophic cardiomyopathy: Prevalence of inactivity and perceived barriers. Open Heart, 3(2), e000484.

Canepa, M., Sorensen, L. L., Pozios, I., Dimaano, V. L., Luo, H. C., Pinheiro, A. C., et al. (2013). Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. The American Journal of Cardiology, 112(8), 1182–1189.

Olivotto, I., Maron, B. J., Tomberli, B., Appelbaum, E., Salton, C., Haas, T. S., et al. (2013). Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 62(5), 449–457.

Sharma, S., Elliott, P., Whyte, G., Jones, S., Mahon, N., Whipp, B., et al. (2000). Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. The American Journal of Cardiology, 86(2), 162–168.

Finocchiaro, G., Haddad, F., Knowles, J. W., Caleshu, C., Pavlovic, A., Homburger, J., et al. (2015). Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: A potential role for comprehensive noninvasive hemodynamic assessment. JACC: Heart Failure, 3(5), 408–418.

Masri, A., Pierson, L. M., Smedira, N. G., Agarwal, S., Lytle, B. W., Naji, P., et al. (2015). Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. American Heart Journal, 169(5), 684–692.e1.

Coats, C. J., Rantell, K., Bartnik, A., Patel, A., Mist, B., McKenna, W. J., et al. (2015). Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circulation: Heart Failure, 8(6), 1022–1031.

Sorajja, P., Allison, T., Hayes, C., Nishimura, R. A., Lam, C. S., & Ommen, S. R. (2012). Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. The American Journal of Cardiology, 109(10), 1494–1498.

Gilligan, D. M., Chan, W. L., Joshi, J., Clarke, P., Fletcher, A., Krikler, S., et al. (1993). A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 21(7), 1672–1679.

Saberi, S., Wheeler, M., Bragg-Gresham, J., Hornsby, W., Agarwal, P. P., Attili, A., et al. (2017). Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: A randomized clinical trial. JAMA, 317(13), 1349–1357.

Food and Drug Administration (2009). Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. https://www.fda.gov/media/77832/download. Accessed 15 May 2020.

Hypertrophic Cardiomyopathy Association. www.4hcm.org. Accessed 15 May 2020.

Cardiomyopathy UK. The heart muscle charity. https://www.cardiomyopathy.org/. Accessed 15 May 2020.

Bois, J. P., Adams, J. C., Kumar, G., Ommen, S. R., Nishimura, R. A., & Klarich, K. W. (2016). Relation between temperature extremes and symptom exacerbation in patients with hypertrophic cardiomyopathy. The American Journal of Cardiology, 117(6), 961–965.

Fortunato de Cano, S., Nicolas Cano, M., de Ribamar Costa Jr., J., Alves Pinheiro Jr., J., Bellio de Mattos Barretto, R., Costa de Souza Le Bihan, D., et al. (2016). Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions, 88(6), 953–960.

Magnusson, P., Morner, S., Gadler, F., & Karlsson, J. (2016). Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators. Health and Quality of Life Outcomes, 14, 62.

Ingles, J., Johnson, R., Sarina, T., Yeates, L., Burns, C., Gray, B., et al. (2015). Social determinants of health in the setting of hypertrophic cardiomyopathy. International Journal of Cardiology, 184, 743–749.

Minto, C., Bauce, B., Calore, C., Rigato, I., Folino, F., Soriani, N., et al. (2015). Is internet use associated with anxiety in patients with and at risk for cardiomyopathy? American Heart Journal, 170(1), 87–95, 95.e1–4.

Thông tin
Thông tin xuất bản

Journal of Patient-Reported Outcomes

Tập 4 Số 1

Thông tin tác giả